Two studies provide additional support for lowering systolic blood pressure to an intensive goal of 120 mmHg – far below the standard guidelines of 140 mmHg – to reduce the risk of heart disease in ...

Strategy reduced nephropathy risky by 21% in patients with type 2 diabetes, study finds. Intensive glucose control with gliclazide (modified release) and other agents reduced the risk of nephropathy ...

We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs ...

Please provide your email address to receive an email when new articles are posted on . Using intensive blood pressure control in patients with stages 4 to 5 chronic kidney disease may delay the onset ...

Please provide your email address to receive an email when new articles are posted on . In patients who had endovascular thrombectomy for acute ischemic stroke with large-vessel occlusion, intensive ...

A new study by researchers at Wake Forest University School of Medicine shows that only 3.5 years of intensive blood pressure control continues to significantly reduce the risk of mild cognitive ...

This carefully designed meta-analysis combined results from 5 recent clinical trials to shed further light on the confusing question of whether intensive glycemic control reduces the risk for ...

Targeting a systolic blood pressure below 130 mm Hg was associated with a 21% decreased risk of all-cause mortality among patients with stage 3 to 4 chronic kidney disease, a meta-analysis found. An ...

Aggressive blood pressure treatment in older hypertensive patients lowers the incidence of cardiovascular events compared to standard therapy, without increasing adverse outcomes. That's the finding ...

SAN FRANCISCO, CA—In the SPRINT trial, patients who were treated to an intensive versus standard blood pressure goal had a lower risk of developing LV conduction disease, which hasn’t been considered ...

The belief that the lower the glucose level the better in patients with type 2 diabetes who are at a high risk for MI or stroke has been called into question by an ongoing NIH-supported trial.